Stockreport
Is Vertex Pharmaceuticals Fairly Priced After Recent Gains and Expanding Pipeline in 2025? [Yahoo! Finance]
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
This article will walk you through what the numbers are really saying about its value. The stock is up 4.1% over the last month and 11.4% year to date, even though the 1 year return is slightly negative at -2.5%. This hints at a mix of renewed optimism and lingering caution after a strong 3 year gain of 48.3%. Recent attention has focused on Vertex's expanding pipeline in cystic fibrosis and non opioid pain treatments, along with growing interest in its gene editing collaborations. Together these have reinforced the long term growth story. At the same time, investors are debating whether these opportunities are fully reflected in today's price or if the market is still underestimating the upside. On our framework the stock scores a 3/6 valuation check , suggesting it looks undervalued on some metrics but not convincingly cheap across the board. Next we will unpack the main valuation approaches investors use for Vertex and, toward the end, explore a more holistic way of judging w
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | VRTX | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
VRTX alerts
VRTX alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
NEWS
NEWS
- How Investors Are Reacting To Vertex Pharmaceuticals (VRTX) Pediatric CASGEVY Data And Accelerated FDA Review [Yahoo! Finance][Yahoo! Finance]
- Sharp Rise in Senior Overdose Deaths Drives Launch of New Healthy Aging Video Program [Yahoo! Finance][Yahoo! Finance]
- Vertex Pharmaceuticals (NASDAQ:VRTX) had its price target raised by analysts at Wells Fargo & Company from $460.00 to $515.00. They now have an "overweight" rating on the stock.[MarketBeat]
- Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.[MarketBeat]
- Down 10%, Should You Buy the Dip on Vertex Pharmaceuticals? [Yahoo! Finance][Yahoo! Finance]
- More
VRTX
SEC Filings
SEC Filings
- 12/5/25 - Form 4
- 12/5/25 - Form 4
- 12/5/25 - Form 4
- VRTX's page on the SEC website
- More